Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation.

ABSTRACT: In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs. We investigated the in vitro antiviral activity against SARS-CoV-2 of several antimalarial drugs. Chloroquine (EC₅₀ = 2.1 μM and EC₉₀ = 3.8 μM), hydroxychloroquine (EC₅₀ = 1.5 μM and EC₉₀ = 3.0 μM), ferroquine (EC₅₀ = 1.5 μM and EC₉₀ = 2.4 μM), desethylamodiaquine (EC₅₀ = 0.52 μM and EC₉₀ = 1.9 μM), mefloquine (EC₅₀ = 1

SUBMITTER: Gendrot M 

PROVIDER: S-EPMC7477610 | biostudies-literature | 2020 Sep - Oct

REPOSITORIES: biostudies-literature